Nanoparticle Tracking Analysis (NTA)

Nanoparticle Tracking Analysis (NTA) is a high-resolution analytical technique used to visualize, track, and size individual nanoparticles in a liquid suspension on a particle-by-particle basis. By tracking the random movement of particles under laser illumination, NTA simultaneously determines their size distribution and concentration (titer). In the context of biologics, it serves as a critical characterization and orthogonal method for determining the physical titer and size distribution of nanoparticles such as AAV vectors and Lipid Nanoparticles (LNPs).

• Legacy Technique: Dynamic Light Scattering (DLS) & Electron Microscopy (EM). DLS provides an average particle size (Z-average) for the entire sample but has low resolution and cannot determine concentration. EM can visualize particles but is complex, not quantitative for concentration, and requires harsh sample preparation.
• NTA is a widely adopted characterization tool for obtaining number-based size distributions and concentration estimates, though results are typically confirmed with orthogonal methods. concentration measurements of nanoparticles directly in a liquid sample.
• Emerging Alternatives: Fluorescence NTA (fNTA) can selectively track labeled particles (e.g., DNA-stained AAVs), providing exploratory data on full/empty ratios. However, this application is still under development and not yet an established regulatory standard.

NTA visualizes and analyzes particles based on two fundamental physical principles: light scattering and Brownian motion.

• Output: The primary outputs are a size distribution graph (particle count vs. size in nanometers) and a calculated particle concentration (e.g., in particles/mL). The report includes metrics like the mean and mode particle size and the D90 (the size below which 90% of the particles lie).
• Interpretation: For AAVs, the size distribution should show a sharp, primary peak with a mode diameter around the expected size (~25-30 nm). The calculated concentration provides the physical capsid titer. The presence of broader distributions or apparent populations at larger sizes may indicate aggregation, which should be confirmed with orthogonal methods.

• High-Resolution Sizing: Provides a number-weighted size distribution, which can resolve different populations in a mixed sample better than DLS.
• Simultaneous Size and Titer: Measures both key parameters in a single analysis.
• Visual Confirmation: The recorded video provides direct visual evidence of the particles being analyzed.

• Sensitive to Sample Preparation: The method's accuracy is highly dependent on diluting the sample into the instrument's optimal concentration range. Over- or under-dilution will lead to significant errors.
• Operator Dependent: Setting key analysis parameters like the camera focus and detection threshold requires expertise and can be a source of variability if not carefully controlled in an SOP.
• Not a Routine QC Method: Due to its complexity and variability, NTA is used as a characterization and orthogonal method, not a validated GMP release test.

While NTA is not typically subjected to a full GMP validation for routine batch release, the method must be formally qualified to ensure the data is reliable for its intended purpose in product characterization and regulatory submissions. This qualification process is performed as a fit-for-purpose study to establish reliability for characterization, rather than a full ICH Q2(R2) validation.

• System Suitability: The instrument's performance must be verified before use, typically with certified polystyrene bead standards of a known size and concentration, to ensure it is operating correctly.
• Robustness: The method is highly sensitive to analysis settings (camera level, detection threshold) and sample preparation (dilution factor). A robustness study is essential to understand the operational limits and ensure consistent performance.
• Fit-for-Purpose Assessment: The goal is to demonstrate a level of precision and accuracy that is "fit-for-purpose." This means the data is proven to be reliable for characterizing the product (e.g., confirming particle size or providing an orthogonal titer estimate), even if the method's variability makes it unsuitable for a narrow QC release specification.

Standardization of NTA methods is critical because results are highly dependent on instrument settings and sample preparation. Key parameters such as dilution factor, detection threshold, camera level, and analysis algorithm must be defined and controlled in the SOP to ensure reproducibility. Reference materials—typically NIST-traceable polystyrene or silica nanoparticle standards with certified size and concentration—are used for system suitability testing and calibration. For biologics, in-house reference lots (e.g., AAV or LNP standards with known titer and size) are often employed to verify consistency over time. Lifecycle management includes periodic requalification of instruments, bridging studies when software or standards change, and orthogonal confirmation (e.g., EM, AUC) to ensure data comparability across labs and studies.

• AAV Gene Therapy: Used to measure physical titer and confirm the size and monodispersity of the viral particles.
• Lipid Nanoparticles (LNPs): A key tool for characterizing LNP-based therapies (e.g., mRNA vaccines and siRNA therapeutics) by measuring their size and concentration.
• Extracellular Vesicles (EVs) / Exosomes: Considered a gold standard method for sizing and quantifying these complex biological nanoparticles.